Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.50 |
| ▸ | PLG | P00747 | 2/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | F11 | P03951 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6154809 | 1.00 | KMT2A (0.54) | KMT2AMEN1LMNARAB9ANAMPT | |
| SCHEMBL25845705 | 0.89 | NAMPT (0.62) | KMT2AMEN1LMNARAB9ANAMPT | |
| SCHEMBL8595935 | 0.84 | KMT2A (0.61) | KMT2AMEN1LMNARAB9ANAMPT | |
| SCHEMBL14428865 | 0.84 | KMT2A (0.62) | KMT2AMEN1LMNARAB9ANAMPT | |
| SCHEMBL8595933 | 0.84 | KMT2A (0.61) | KMT2AMEN1LMNARAB9ANAMPT | |
| SCHEMBL6153818 | 0.83 | MAPK14 (0.54) | KMT2AMEN1LMNARAB9ANAMPT | |
| SCHEMBL3696100 | 0.83 | MEN1 (0.66) | KMT2AMEN1LMNARAB9ANAMPT | |
| SCHEMBL3696104 | 0.83 | MEN1 (0.66) | KMT2AMEN1LMNARAB9ANAMPT | |
| SCHEMBL6153470 | 0.83 | NAMPT (0.56) | KMT2AMEN1LMNARAB9ANAMPT | |
| Hydrochloric Acid SCHEMBL8597276 | 0.82 | KMT2A (0.60) | KMT2AMEN1LMNARAB9ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | KMT2A 1307/4885MEN1 1993/4885LMNA 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.